Speakers were great and presented valuable data. Comprehensive conference and
Tina T., Associate Scientist, Biogen Idec
overview of most current inflammation targets and therapies.
Inflammation is a component of many chronic diseases or conditions whose prevalence, as the population ages, is increasing. Hence there is great interest in developing oral medications similar in their convenience to the current standard option of non-steroidal anti-inflammatory drugs (NSAIDS) and Cox2 inhibitors but with safer profiles for long-term use. Immunotherapies based on therapeutic antibodies have met with much success in the past decade by combating the immunological underpinnings of inflammation. However because of biologics’ less convenient formulation and expense, the spotlight is back on smaller molecules that have oral bioavailability potential and can be produced by organic chemistry approaches. The recent FDA approval of a small molecule JAK kinase inhibitor to fight inflammation, has also contributed to the excitement over small molecule approaches for anti-inflammatories.
In its fourth year, Cambridge Healthtech Institute’s Inflammation Inhibitors meeting will continue to feature medicinal chemistry-focused case studies of small molecule drug candidates progressing in pre-clinical and clinical development. New this year, larger synthetic small molecules such as macrocyclic peptides that have biovailability potential, will also be covered; a few such compounds have recently entered the clinic for inflammation conditions. In addition to featuring the kinase inhibitors progressing in drug development, drug leads directed against non-kinase and newer targets will be a part of the meeting. Join fellow drug discovery scientists for this day-and-a-half meeting that is in the first half of CHI's larger Drug Discovery Chemistry event.
Topics may include, but are not limited to:
- Kinase inflammation targets (JAK, SYK, BTK, IRAK4, PIM1, RIP and others)
- Cytokines and cytokine receptor targets
- Newer approaches for discovering drug leads (PPI approaches, covalent inhibitors)
- Inhibiting newer types of targets such as chaperones, lipid metabolism regulators, epigenetic modifiers
- Shared targets between inflammation and other diseases or biological processes (cardiovascular, CNS, aging, regeneration and repair)
If you would like to submit a proposal to give a presentation at this meeting, please click here.
The deadline for submission is September 22, 2014
All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
For more details on the conference, please contact:
Anjani Shah, Ph.D.
Cambridge Healthtech Institute
Phone: (914) 723-0251
For partnering and sponsorship information, please contact:
Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5412